排序方式: 共有57条查询结果,搜索用时 0 毫秒
51.
52.
53.
54.
55.
Kenneth Dickstein 《Trials》2001,2(5):240-4
The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The trials differed, however, in terms of their primary hypothesis, study design, and treatment regimens, and this must be taken into consideration when comparing and interpreting the data from these studies. The data are in many ways complementary, and add to our understanding of the optimal treatment of symptomatic heart failure. Additional studies are needed, however, to fully define the role of angiotensin II receptor antagonists in the management of this very heterogeneous group of patients. 相似文献
56.
57.
Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients
with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment
in patients with preserved LV function has not been known. The results from the Heart Outcome Prevention Evaluation trial
have indicated that long-term treatment with ramipril leads to a significant reduction in cardiovascular events in patients
with atherosclerotic disease, including those with prior myocardial infarction and preserved LV function. These results suggest
that long-term angiotensin-converting enzyme inhibition should also be considered in post-infarction patients with normal
cardiac function. 相似文献